TY - JOUR
T1 - A novel 31-amino-acid-length endothelin, ET-1(1-31), can act as a biologically active peptide for vascular smooth muscle cells
AU - Nagata, Noriko
AU - Niwa, Yasuharu
AU - Nakaya, Yutaka
PY - 2000/8/28
Y1 - 2000/8/28
N2 - Human chymase produces a novel endothelin-1 with 31 amino-acid length {ET-1(1-31)}, which is longer than conventional ET-1, {ET-1(1-21)}. The aim of our study was to investigate the role of ET-1(1-31) on porcine coronary vascular smooth muscle cell (VSMC). Although the increase in [Ca2+](i) by ET-1(1-31) was 10 times weaker than that of ET-1(1-21), ET-1(1-31) showed equivalent potency in VSMC proliferation, c-fos/c-myc mRNA expression and cell cycle analysis with ET-1(1-21). ET-1(1-31) significantly induced expression of cyclin D1 but not those of cyclin D2 or D3. These effects were specifically inhibited by BQ485, an ET(A) receptor antagonist, although that of ET-1(1-21) was not specific to BQ485, suggesting different receptor specificity from ET-1(1-21). These results indicate that ET-1(1-31) also can involve a VSMC proliferation process such as atherosclerosis, although it has weaker vasoconstricting potency and different receptor subtypes on VSMC from those of ET-1(1-21). (C) 2000 Academic Press.
AB - Human chymase produces a novel endothelin-1 with 31 amino-acid length {ET-1(1-31)}, which is longer than conventional ET-1, {ET-1(1-21)}. The aim of our study was to investigate the role of ET-1(1-31) on porcine coronary vascular smooth muscle cell (VSMC). Although the increase in [Ca2+](i) by ET-1(1-31) was 10 times weaker than that of ET-1(1-21), ET-1(1-31) showed equivalent potency in VSMC proliferation, c-fos/c-myc mRNA expression and cell cycle analysis with ET-1(1-21). ET-1(1-31) significantly induced expression of cyclin D1 but not those of cyclin D2 or D3. These effects were specifically inhibited by BQ485, an ET(A) receptor antagonist, although that of ET-1(1-21) was not specific to BQ485, suggesting different receptor specificity from ET-1(1-21). These results indicate that ET-1(1-31) also can involve a VSMC proliferation process such as atherosclerosis, although it has weaker vasoconstricting potency and different receptor subtypes on VSMC from those of ET-1(1-21). (C) 2000 Academic Press.
UR - http://www.scopus.com/inward/record.url?scp=0034726735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034726735&partnerID=8YFLogxK
U2 - 10.1006/bbrc.2000.3292
DO - 10.1006/bbrc.2000.3292
M3 - Article
C2 - 10964709
AN - SCOPUS:0034726735
SN - 0006-291X
VL - 275
SP - 595
EP - 600
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -